Cereno Scientific has signed an agreement with a leading, global CRO for the implementation of the phase IIb study with the drug candidate CS1 in pulmonary arterial hypertension (PAH). According to the company, the CRO has deep expertise in the disease and extensive experience in clinical trials in this indication, as well as a well-established network of experienced investigators and patients. The planned Phase IIb study is a global, placebo-controlled study that is expected to begin in the first half of 2026, subject to regulatory approvals.
|
Published July 4, 2025
Cereno Scientific selects CRO for Phase IIb study
Notes
Johnson & Johnson acquires Halda Therapeutics for $3 billion
Magle Group submits application for EmboCept S
Quia Pharma is delisted from Nasdaq
Stenocare acquires CannGros
Lundbeck enters the fight for Avadel
Klaria's partner CNX starts production of migraine film
Sofinnova Partners raises EUR 650 million in new fund
NEWSLETTER
Today's news roundup
News roundup Monday, November 17
Upcoming events
MedTech Summit 2026
A new, much-needed MedTech forum in one of Europe's leading life science clusters. As the first event of its kind...
Recommended
Pila Pharma stands out in next-generation obesity pipeline
Novo Nordisk challenges Pfizer in billion-dollar battle for Metsera
New major investment will strengthen Europe's life science sector
The pharmaceutical sector is riding a USD 61,6 billion R&D wave
SwedenBIO wants to give growth power to the industry
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account